| Issue Type | XXXX |
|---|---|
| Country | United Kingdom |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2029-06-03 |
| Par Value | 100000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 800.00 |
| Coupon | 0.375 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 800 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This Astrazeneca plc corporate note has a X.X % fixed rate coupon paid on a XXXX basis. It was issued on MAR 12, 2000 with an issue size of XXX million EUR and matures on DEC 9, 2000 with a last coupon date of FEB 28, 2020. |
AstraZeneca plc, founded in 1999 and headquartered in Cambridge, UK, is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of prescription medicines. The company focuses on oncology, cardiovascular, renal, and respiratory therapies, alongside a notable pipeline in rare diseases and vaccine development.